All In Biotech

Drug Trial Radar · NCT06590558

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)

Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Aug 4, 2025

Primary completion

May 17, 2027

Study completion May 17, 2027

Sponsor

Sponsor type
NIH
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/Ib trial tests the safety, side effects, best dose, and effectiveness of ASTX660 (tolinapant) in combination with eribulin mesylate (eribulin) in treating patients with triple negative breast cancer that cannot be removed by surgery (unresectable) or that has spread to nearby tissues or lymph nodes (locally advanced) or to other places in the body (metastatic). Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, needed for tumor cell survival. Chemotherapy drugs, such as eribulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tolinapant in combination with eribulin may be safe, tolerable, and/or effective in treating patients with unresectable, locally advanced, or metastatic triple negative breast cancer.

Conditions

  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Invasive Breast Carcinoma
  • Locally Advanced HER2-Negative Breast Carcinoma
  • Locally Advanced Hormone Receptor-Positive Breast Carcinoma
  • Locally Advanced Triple-Negative Breast Carcinoma
  • Metastatic HER2-Negative Breast Carcinoma
  • Metastatic Hormone Receptor-Positive Breast Carcinoma
  • Metastatic Triple-Negative Breast Carcinoma
  • Unresectable HER2-Negative Breast Carcinoma
  • Unresectable Hormone Receptor-Positive Breast Carcinoma
  • Unresectable Triple-Negative Breast Carcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo tissue biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • Eribulin MesylateDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • TolinapantDrug

    Given PO

  • X-Ray ImagingProcedure

    Undergo chest X-ray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: Up to 3 months after last dose of study drug
  2. Dose-limiting toxicities (DLT)Time frame: Up to 4 weeks following the first administration (cycle 1 day 1) of the investigational therapy
  3. Maximum tolerated dose (MTD)Time frame: Up to 4 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.